From: Repositioning drugs by targeting network modules: a Parkinson’s disease case study
Compound ID | Compound Name | Score | Drugbank | DrugName | Class |
---|---|---|---|---|---|
CID5757 | CID5757 | 290.3 | DB00783 | Estradiol | Steroids and steroid derivatives |
CID445154 | SAM001246888 | 253.9 | DB02709 | Resveratrol | Stilbenes |
CID444795 | Retinoic Acid | 248.9 | DB00523 | Alitretinoin | Prenol lipids |
CID5538 | Accutane Roche | 246.3 | DB00755 | Tretinoin | Lipids and lipid-like molecules |
CID5282379 | Isotretinoin (USP) | 246.3 | DB00982 | Isotretinoin | Prenol lipids |
CID5280961 | NCGC00025005–02 | 244.3 | DB01645 | Genistein | Isoflavonoids |
CID5460439 | Rapamune | 224.9 | DB00877 | Sirolimus | Macrolide lactams |
CID6436030 | Perceiva | 224.9 | DB00877 | Sirolimus | Macrolide lactams |
CID667476 | follidiene | 199 | DB00890 | Dienestrol | Phenylpropanoids and polyketides |
CID448537 | oekolp | 199 | DB00255 | Diethylstilbestrol | Phenylpropanoids and polyketides |
CID6010 | component of Tylosterone | 199 | DB06710 | Methyltestosterone | Lipids and lipid-like molecules |
CID2756 | C4522_SIGMA | 198.2 | DB00501 | Cimetidine | Organoheterocyclic compounds |